APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rhabdomyosarcoma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Rhabdomyosarcoma Drug Industry Research Report 2026

22 December 2025136 pages

Choose your research edition.

Industry ResearchRhabdomyosarcoma Drug Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Rhabdomyosarcoma Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Rhabdomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rhabdomyosarcoma Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Rhabdomyosarcoma Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Rhabdomyosarcoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Rhabdomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Rhabdomyosarcoma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Rhabdomyosarcoma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Rhabdomyosarcoma Drug include Eisai Co Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, Tarveda Therapeutics Inc, Taiwan Liposome Company Ltd, Taiho Pharmaceutical Co Ltd, Noxxon Pharma AG and NantKwest Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Rhabdomyosarcoma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Rhabdomyosarcoma Drug Market by Company

Eisai Co Ltd

Novartis AG

Pfizer Inc

Bristol-Myers Squibb Co

Tarveda Therapeutics Inc

Taiwan Liposome Company Ltd

Taiho Pharmaceutical Co Ltd

Noxxon Pharma AG

NantKwest Inc

MacroGenics Inc

Ipsen SA

Iproteos SL

Exelixis Inc

Epizyme Inc

Celgene Corp

Boehringer Ingelheim GmbH

Bellicum Pharmaceuticals Inc

Rhabdomyosarcoma Drug Segment by Type

ARI-4175

AT-69

Celyvir

Enoblituzumab

Axitinib

Crizotinib

Others

Rhabdomyosarcoma Drug Segment by Application

Clinic

Hospital

Research Center

Others

Rhabdomyosarcoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rhabdomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rhabdomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rhabdomyosarcoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Rhabdomyosarcoma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Rhabdomyosarcoma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Rhabdomyosarcoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Rhabdomyosarcoma Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Rhabdomyosarcoma Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Rhabdomyosarcoma Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Rhabdomyosarcoma Drug Revenue of Manufacturers (2021-2026) Table 9. Global Rhabdomyosarcoma Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Rhabdomyosarcoma Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Rhabdomyosarcoma Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Rhabdomyosarcoma Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Rhabdomyosarcoma Drug, Product Type & Application Table 14. Global Rhabdomyosarcoma Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Rhabdomyosarcoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eisai Co Ltd Company Information Table 19. Eisai Co Ltd Business Overview Table 20. Eisai Co Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 22. Eisai Co Ltd Recent Developments Table 23. Novartis AG Company Information Table 24. Novartis AG Business Overview Table 25. Novartis AG Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Novartis AG Rhabdomyosarcoma Drug Product Portfolio Table 27. Novartis AG Recent Developments Table 28. Pfizer Inc Company Information Table 29. Pfizer Inc Business Overview Table 30. Pfizer Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio Table 32. Pfizer Inc Recent Developments Table 33. Bristol-Myers Squibb Co Company Information Table 34. Bristol-Myers Squibb Co Business Overview Table 35. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio Table 37. Bristol-Myers Squibb Co Recent Developments Table 38. Tarveda Therapeutics Inc Company Information Table 39. Tarveda Therapeutics Inc Business Overview Table 40. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio Table 42. Tarveda Therapeutics Inc Recent Developments Table 43. Taiwan Liposome Company Ltd Company Information Table 44. Taiwan Liposome Company Ltd Business Overview Table 45. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio Table 47. Taiwan Liposome Company Ltd Recent Developments Table 48. Taiho Pharmaceutical Co Ltd Company Information Table 49. Taiho Pharmaceutical Co Ltd Business Overview Table 50. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 52. Taiho Pharmaceutical Co Ltd Recent Developments Table 53. Noxxon Pharma AG Company Information Table 54. Noxxon Pharma AG Business Overview Table 55. Noxxon Pharma AG Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio Table 57. Noxxon Pharma AG Recent Developments Table 58. NantKwest Inc Company Information Table 59. NantKwest Inc Business Overview Table 60. NantKwest Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio Table 62. NantKwest Inc Recent Developments Table 63. MacroGenics Inc Company Information Table 64. MacroGenics Inc Business Overview Table 65. MacroGenics Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio Table 67. MacroGenics Inc Recent Developments Table 68. Ipsen SA Company Information Table 69. Ipsen SA Business Overview Table 70. Ipsen SA Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Ipsen SA Rhabdomyosarcoma Drug Product Portfolio Table 72. Ipsen SA Recent Developments Table 73. Iproteos SL Company Information Table 74. Iproteos SL Business Overview Table 75. Iproteos SL Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Iproteos SL Rhabdomyosarcoma Drug Product Portfolio Table 77. Iproteos SL Recent Developments Table 78. Exelixis Inc Company Information Table 79. Exelixis Inc Business Overview Table 80. Exelixis Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio Table 82. Exelixis Inc Recent Developments Table 83. Epizyme Inc Company Information Table 84. Epizyme Inc Business Overview Table 85. Epizyme Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio Table 87. Epizyme Inc Recent Developments Table 88. Celgene Corp Company Information Table 89. Celgene Corp Business Overview Table 90. Celgene Corp Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Celgene Corp Rhabdomyosarcoma Drug Product Portfolio Table 92. Celgene Corp Recent Developments Table 93. Boehringer Ingelheim GmbH Company Information Table 94. Boehringer Ingelheim GmbH Business Overview Table 95. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio Table 97. Boehringer Ingelheim GmbH Recent Developments Table 98. Bellicum Pharmaceuticals Inc Company Information Table 99. Bellicum Pharmaceuticals Inc Business Overview Table 100. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio Table 102. Bellicum Pharmaceuticals Inc Recent Developments Table 103. Global Rhabdomyosarcoma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Rhabdomyosarcoma Drug Sales by Region (2021-2026) & (k units) Table 105. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2021-2026) Table 106. Global Rhabdomyosarcoma Drug Sales by Region (2027-2032) & (k units) Table 107. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2027-2032) Table 108. Global Rhabdomyosarcoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2026) Table 110. Global Rhabdomyosarcoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2027-2032) Table 112. North America Rhabdomyosarcoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 114. North America Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 115. North America Rhabdomyosarcoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Rhabdomyosarcoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Rhabdomyosarcoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 119. Europe Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 120. Europe Rhabdomyosarcoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Rhabdomyosarcoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Rhabdomyosarcoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 124. Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 125. Asia Pacific Rhabdomyosarcoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Rhabdomyosarcoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Rhabdomyosarcoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 129. South America Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 130. South America Rhabdomyosarcoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Rhabdomyosarcoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Rhabdomyosarcoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 134. Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 135. Middle East and Africa Rhabdomyosarcoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Rhabdomyosarcoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 138. Global Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 139. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2026) Table 140. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2027-2032) Table 141. Global Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2026) Table 144. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2027-2032) Table 145. Global Rhabdomyosarcoma Drug Price by Type (2021-2026) & (US$/unit) Table 146. Global Rhabdomyosarcoma Drug Price by Type (2027-2032) & (US$/unit) Table 147. Global Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 148. Global Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 149. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2026) Table 150. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2027-2032) Table 151. Global Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2026) Table 154. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2027-2032) Table 155. Global Rhabdomyosarcoma Drug Price by Application (2021-2026) & (US$/unit) Table 156. Global Rhabdomyosarcoma Drug Price by Application (2027-2032) & (US$/unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Rhabdomyosarcoma Drug Distributors List Table 160. Rhabdomyosarcoma Drug Customers List Table 161. Rhabdomyosarcoma Drug Industry Trends Table 162. Rhabdomyosarcoma Drug Industry Drivers Table 163. Rhabdomyosarcoma Drug Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Rhabdomyosarcoma Drug Product Image Figure 5. Global Rhabdomyosarcoma Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Rhabdomyosarcoma Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Rhabdomyosarcoma Drug Sales (2021-2032) & (k units) Figure 8. Global Rhabdomyosarcoma Drug Average Price (US$/unit) & (2021-2032) Figure 9. ARI-4175 Product Image Figure 10. AT-69 Product Image Figure 11. Celyvir Product Image Figure 12. Enoblituzumab Product Image Figure 13. Axitinib Product Image Figure 14. Crizotinib Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. Research Center Product Image Figure 19. Others Product Image Figure 20. Global Rhabdomyosarcoma Drug Revenue Share by Manufacturers in 2025 Figure 21. Global Manufacturers of Rhabdomyosarcoma Drug, Manufacturing Sites & Headquarters Figure 22. Global Top 5 and 10 Rhabdomyosarcoma Drug Players Market Share by Revenue in 2025 Figure 23. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Rhabdomyosarcoma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 25. Global Rhabdomyosarcoma Drug Sales by Region in 2025 Figure 26. Global Rhabdomyosarcoma Drug Revenue by Region in 2025 Figure 27. North America Rhabdomyosarcoma Drug Market Size by Country in 2025 Figure 28. North America Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 29. North America Rhabdomyosarcoma Drug Revenue Market Share by Country (2021-2032) Figure 30. United States Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Canada Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Mexico Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Europe Rhabdomyosarcoma Drug Market Size by Country in 2025 Figure 34. Europe Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 35. Europe Rhabdomyosarcoma Drug Revenue Market Share by Country (2021-2032) Figure 36. Germany Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. France Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. U.K. Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Italy Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Russia Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Spain Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Netherlands Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Switzerland Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Sweden Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Poland Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Asia Pacific Rhabdomyosarcoma Drug Market Size by Country in 2025 Figure 47. Asia Pacific Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 48. Asia Pacific Rhabdomyosarcoma Drug Revenue Market Share by Country (2021-2032) Figure 49. China Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Japan Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South Korea Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. India Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Australia Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Taiwan Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. South America Rhabdomyosarcoma Drug Market Size by Country in 2025 Figure 58. South America Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 59. South America Rhabdomyosarcoma Drug Revenue Market Share by Country (2021-2032) Figure 60. Brazil Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Argentina Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Chile Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Rhabdomyosarcoma Drug Market Size by Country in 2025 Figure 64. Middle East and Africa Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Rhabdomyosarcoma Drug Revenue Market Share by Country (2021-2032) Figure 66. Egypt Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Rhabdomyosarcoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032) Figure 72. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032) Figure 73. Global Rhabdomyosarcoma Drug Price (US$/unit) by Type (2021-2032) Figure 74. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032) Figure 75. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032) Figure 76. Global Rhabdomyosarcoma Drug Price (US$/unit) by Application (2021-2032) Figure 77. Rhabdomyosarcoma Drug Value Chain Figure 78. Rhabdomyosarcoma Drug Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Rhabdomyosarcoma Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • ARI-4175
  • AT-69
  • Celyvir
  • Enoblituzumab
  • Axitinib
  • Crizotinib
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Eisai Co Ltd
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Co
  • Tarveda Therapeutics Inc
  • Taiwan Liposome Company Ltd
  • Taiho Pharmaceutical Co Ltd
  • Noxxon Pharma AG
  • NantKwest Inc
  • MacroGenics Inc
  • Ipsen SA
  • Iproteos SL
  • Exelixis Inc
  • Epizyme Inc
  • Celgene Corp
  • Boehringer Ingelheim GmbH
  • Bellicum Pharmaceuticals Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Rhabdomyosarcoma Drug Market Size (2021-2032)
  4. 2.2.2 Global Rhabdomyosarcoma Drug Sales (2021-2032)
  5. 2.2.3 Global Rhabdomyosarcoma Drug Market Average Price (2021-2032)
  6. 2.3 Rhabdomyosarcoma Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 ARI-4175
  9. 2.3.3 AT-69
  10. 2.3.4 Celyvir
  11. 2.3.5 Enoblituzumab
  12. 2.3.6 Axitinib
  13. 2.3.7 Crizotinib
  14. 2.3.8 Others
  15. 2.4 Rhabdomyosarcoma Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 Research Center
  20. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Rhabdomyosarcoma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Rhabdomyosarcoma Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Rhabdomyosarcoma Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Rhabdomyosarcoma Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Rhabdomyosarcoma Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Rhabdomyosarcoma Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Rhabdomyosarcoma Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Rhabdomyosarcoma Drug, Established Date
  9. 3.9 Global Rhabdomyosarcoma Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eisai Co Ltd
  2. 4.1.1 Eisai Co Ltd Company Information
  3. 4.1.2 Eisai Co Ltd Business Overview
  4. 4.1.3 Eisai Co Ltd Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  6. 4.1.5 Eisai Co Ltd Recent Developments
  7. 4.2 Novartis AG
  8. 4.2.1 Novartis AG Company Information
  9. 4.2.2 Novartis AG Business Overview
  10. 4.2.3 Novartis AG Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novartis AG Rhabdomyosarcoma Drug Product Portfolio
  12. 4.2.5 Novartis AG Recent Developments
  13. 4.3 Pfizer Inc
  14. 4.3.1 Pfizer Inc Company Information
  15. 4.3.2 Pfizer Inc Business Overview
  16. 4.3.3 Pfizer Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio
  18. 4.3.5 Pfizer Inc Recent Developments
  19. 4.4 Bristol-Myers Squibb Co
  20. 4.4.1 Bristol-Myers Squibb Co Company Information
  21. 4.4.2 Bristol-Myers Squibb Co Business Overview
  22. 4.4.3 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio
  24. 4.4.5 Bristol-Myers Squibb Co Recent Developments
  25. 4.5 Tarveda Therapeutics Inc
  26. 4.5.1 Tarveda Therapeutics Inc Company Information
  27. 4.5.2 Tarveda Therapeutics Inc Business Overview
  28. 4.5.3 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio
  30. 4.5.5 Tarveda Therapeutics Inc Recent Developments
  31. 4.6 Taiwan Liposome Company Ltd
  32. 4.6.1 Taiwan Liposome Company Ltd Company Information
  33. 4.6.2 Taiwan Liposome Company Ltd Business Overview
  34. 4.6.3 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio
  36. 4.6.5 Taiwan Liposome Company Ltd Recent Developments
  37. 4.7 Taiho Pharmaceutical Co Ltd
  38. 4.7.1 Taiho Pharmaceutical Co Ltd Company Information
  39. 4.7.2 Taiho Pharmaceutical Co Ltd Business Overview
  40. 4.7.3 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  42. 4.7.5 Taiho Pharmaceutical Co Ltd Recent Developments
  43. 4.8 Noxxon Pharma AG
  44. 4.8.1 Noxxon Pharma AG Company Information
  45. 4.8.2 Noxxon Pharma AG Business Overview
  46. 4.8.3 Noxxon Pharma AG Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio
  48. 4.8.5 Noxxon Pharma AG Recent Developments
  49. 4.9 NantKwest Inc
  50. 4.9.1 NantKwest Inc Company Information
  51. 4.9.2 NantKwest Inc Business Overview
  52. 4.9.3 NantKwest Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio
  54. 4.9.5 NantKwest Inc Recent Developments
  55. 4.10 MacroGenics Inc
  56. 4.10.1 MacroGenics Inc Company Information
  57. 4.10.2 MacroGenics Inc Business Overview
  58. 4.10.3 MacroGenics Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio
  60. 4.10.5 MacroGenics Inc Recent Developments
  61. 4.11 Ipsen SA
  62. 4.11.1 Ipsen SA Company Information
  63. 4.11.2 Ipsen SA Business Overview
  64. 4.11.3 Ipsen SA Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Ipsen SA Rhabdomyosarcoma Drug Product Portfolio
  66. 4.11.5 Ipsen SA Recent Developments
  67. 4.12 Iproteos SL
  68. 4.12.1 Iproteos SL Company Information
  69. 4.12.2 Iproteos SL Business Overview
  70. 4.12.3 Iproteos SL Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Iproteos SL Rhabdomyosarcoma Drug Product Portfolio
  72. 4.12.5 Iproteos SL Recent Developments
  73. 4.13 Exelixis Inc
  74. 4.13.1 Exelixis Inc Company Information
  75. 4.13.2 Exelixis Inc Business Overview
  76. 4.13.3 Exelixis Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio
  78. 4.13.5 Exelixis Inc Recent Developments
  79. 4.14 Epizyme Inc
  80. 4.14.1 Epizyme Inc Company Information
  81. 4.14.2 Epizyme Inc Business Overview
  82. 4.14.3 Epizyme Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio
  84. 4.14.5 Epizyme Inc Recent Developments
  85. 4.15 Celgene Corp
  86. 4.15.1 Celgene Corp Company Information
  87. 4.15.2 Celgene Corp Business Overview
  88. 4.15.3 Celgene Corp Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Celgene Corp Rhabdomyosarcoma Drug Product Portfolio
  90. 4.15.5 Celgene Corp Recent Developments
  91. 4.16 Boehringer Ingelheim GmbH
  92. 4.16.1 Boehringer Ingelheim GmbH Company Information
  93. 4.16.2 Boehringer Ingelheim GmbH Business Overview
  94. 4.16.3 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio
  96. 4.16.5 Boehringer Ingelheim GmbH Recent Developments
  97. 4.17 Bellicum Pharmaceuticals Inc
  98. 4.17.1 Bellicum Pharmaceuticals Inc Company Information
  99. 4.17.2 Bellicum Pharmaceuticals Inc Business Overview
  100. 4.17.3 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio
  102. 4.17.5 Bellicum Pharmaceuticals Inc Recent Developments
5 Global Rhabdomyosarcoma Drug Market Scenario by Region
  1. 5.1 Global Rhabdomyosarcoma Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Rhabdomyosarcoma Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Rhabdomyosarcoma Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Rhabdomyosarcoma Drug Sales by Region: 2027-2032
  5. 5.3 Global Rhabdomyosarcoma Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Rhabdomyosarcoma Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Rhabdomyosarcoma Drug Revenue by Region: 2027-2032
  8. 5.4 North America Rhabdomyosarcoma Drug Market Facts & Figures by Country
  9. 5.4.1 North America Rhabdomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Rhabdomyosarcoma Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Rhabdomyosarcoma Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Rhabdomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Rhabdomyosarcoma Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Rhabdomyosarcoma Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Rhabdomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Rhabdomyosarcoma Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Rhabdomyosarcoma Drug Market Facts & Figures by Country
  41. 5.7.1 South America Rhabdomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Rhabdomyosarcoma Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Rhabdomyosarcoma Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Rhabdomyosarcoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Rhabdomyosarcoma Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Rhabdomyosarcoma Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Rhabdomyosarcoma Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Rhabdomyosarcoma Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Rhabdomyosarcoma Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Rhabdomyosarcoma Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Rhabdomyosarcoma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Rhabdomyosarcoma Drug Value Chain Analysis
  2. 8.1.1 Rhabdomyosarcoma Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Rhabdomyosarcoma Drug Production Mode & Process
  5. 8.2 Rhabdomyosarcoma Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Rhabdomyosarcoma Drug Distributors
  8. 8.2.3 Rhabdomyosarcoma Drug Customers
9 Global Rhabdomyosarcoma Drug Analyzing Market Dynamics
  1. 9.1 Rhabdomyosarcoma Drug Industry Trends
  2. 9.2 Rhabdomyosarcoma Drug Industry Drivers
  3. 9.3 Rhabdomyosarcoma Drug Industry Opportunities and Challenges
  4. 9.4 Rhabdomyosarcoma Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst